Drugs / LPM526000133
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06793995 | Feb → Oct 2025 overdue | Alzheimer disease, Parkinson disease | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LPM526000133 | “LPM526000133 Fumarate Capsules (LY03017)” NCT06793995 ↗ |
| Known as | LY03017 | “LPM526000133 Fumarate Capsules (LY03017)” NCT06793995 ↗ |
| Route | Oral | “single dose，administered orally” NCT06793995 ↗ |